

## Sensorion Announces its Presence in San Francisco during the 38<sup>th</sup> annual J.P. Morgan Healthcare Conference

**Montpellier, 10 January, 2020 – Sensorion (FR0012596468 – ALSEN)** a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces that its management team, including CEO Nawal Ouzren and CBO Juergen Heitmann, will be present in San Francisco, USA, during the 38<sup>th</sup> annual J.P. Morgan Healthcare Conference, to be held January 13-16, 2020.

Sensorion will meet with potential partners and investors to highlight the latest progress made on SENS-401 in sudden sensorineural hearing loss (SSNHL), including new, [non-dilutive funding](#) for the Phase 2 trial, the recent [Positive Data Safety Monitoring Board Review](#) as well as progress on the gene therapy programs.

### About Sensorion

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL). Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases enabling it to select the best targets and modalities for drug candidates. The Company has also identified biomarkers to improve diagnosis and treatment of these underserved illnesses. Sensorion has launched in the second half of 2019 two preclinical gene therapy programs aiming at correcting hereditary monogenic forms of deafness including Usher Type 1 and deafness caused by a mutation of the gene encoding for Otoferlin. The Company is uniquely placed through its platforms and pipeline of potential therapeutics to make a lasting positive impact on hundreds of thousands of people with inner ear related disorders; a significant global unmet medical need.

[www.sensorion-pharma.com](http://www.sensorion-pharma.com)

### Contacts

#### Financial advisor

Catherine Leveau

[catherine.leveau@sensorion-pharma.com](mailto:catherine.leveau@sensorion-pharma.com)

+33 4 67 20 77 30

#### Financial Communication

LifeSci Advisors - Sophie Baumont

[sophie@lifesciadvisors.com](mailto:sophie@lifesciadvisors.com)

+33 6 27 74 74 49

Label: **SENSORION**  
ISIN: **FR0012596468**  
Mnemonic: **ALSEN**



### Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the "Document de reference" registration document filed with the "Autorité des Marchés Financiers" (AMF French Financial Market Authority) on September 7th, 2017 under n°R.17-062 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.